SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference [Yahoo! Finance]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Yahoo! Finance
company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company's Chairman and CEO, will present an overview of the company at the upcoming 23 rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m. ET. The company will also participate in virtual 1:1 meetings, and a replay of Mr. Reich's presentation will be archived on the company website for up to one year. During the presentation, Mr. Reich will highlight the latest developments and upcoming milestones from the company's lead clinical program, SAB-142, a novel biologic being developed for delaying onset and progression of type 1 diabetes in adults and children, as well as partnership and investment opportunities. Mr. Reich's presentation is entitled, “Human Anti Thymocyte Biologic Developed to Delay Onset or Progression of Type 1 Diabetes.” This fully virtu
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors [Yahoo! Finance]Yahoo! Finance
- SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsGlobeNewswire
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.MarketBeat
- SAB Biotherapeutics Provides SAB-142 Trial Update [Yahoo! Finance]Yahoo! Finance
SABS
Earnings
- 8/21/23 - Beat
SABS
Sec Filings
- 4/15/24 - Form 8-K
- 3/29/24 - Form 8-K
- 3/29/24 - Form 10-K
- SABS's page on the SEC website